tubulin polymerization promoting protein family member 3Genealiases: CGI-38 · TPPP/p20 · p20 · p25gamma
Q-omics provides the consensus-scored TPPP3 profile across patient tissues and cancer cell-line models. TPPP3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TPPP3 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, TPPP3 protein abundance shows 25,622 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ACC, BLCA, and LUAD as cancer lineages where TPPP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TPPP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TPPP3 survival associations across molecular data types. TPPP3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TPPP3 RNA expression–survival associations across cancer types. High TPPP3 expression shows unfavorable associations in ACC, BLCA, MESO, UVM, KIRP and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TPPP3 RNA expression.
This table summarizes TPPP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TPPP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TPPP3 shows lower tumor expression in BLCA, LUAD, KICH, KIRP and LUSC and higher tumor expression in KIRC. The BLCA box plot shows higher TPPP3 RNA expression in normal versus tumor tissue (log2 FC = −2.045, t-test p < 0.001).
This table shows molecular features associated with TPPP3 in patient tissues and cancer cell lines. In patient samples, TPPP3 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, TPPP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and SOFT_TISSUE.
